Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure

Journal of Cardiology

Volumn 63, Issue 6, 2014, Pages 418-423

  Tasal, Abdurrahman ^a   Erturk, Mehmet ^b   Uyarel, Huseyin ^a   Karakurt, Huseyin ^b   Bacaksiz, Ahmet ^a   Vatankulu, Mehmet Akif ^a   Turfan, Murat ^a   Sonmez, Osman ^a   Erdogan, Ercan ^a   Ergelen, Mehmet ^a  

^a Bezmialem Foundation University   (Turkey)

^b MEHMET AKIF ERSOY THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acute decompensated heart failure; Levosimendan; Neutrophil to lymphocyte ratio

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; PREDICTIVE VALUE; RISK FACTOR; ACUTE DISEASE; AGED; BLOOD; DISEASE COURSE; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; RETROSPECTIVE STUDY;

ACUTE DISEASE; AGED; CARDIOTONIC AGENTS; DISEASE PROGRESSION; DOBUTAMINE; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; PYRIDAZINES; RETROSPECTIVE STUDIES;

EID: 84902135275     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.10.009     Document Type: Article

References (36)

1. Reichlin T., Socrates T., Egli P., Potocki M., Breidthardt T., Arenja N., Meissner J., Noveanu M., Reiter M., Twerenbold R., Schaub N., Buser A., Mueller C. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 2010, 56:944-951.
2. Engström G., Melander O., Hedblad B. Leukocyte count and incidence of hospitalizations due to heart failure. Circ Heart Fail 2009, 2:217-222.
3. Cooper H.A., Exner D.V., Waclawiw M.A., Domanski M.J. White blood count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1999, 84:525-527.
4. Azab B., Zaher M., Weiserbs K.F., Torbey E., Lacossiere K., Gaddam S., Gobunsuy R., Jadonath S., Baldari D., McCord D., Lafferty J. Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol 2010, 106:470-476.
5. Gibson P.H., Cuthbertson B.H., Croal B.L., Rae D., El-Shafei H., Gibson G., Jeffrey R.R., Buchan K.G., Hillis G.S. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010, 105:186-191.
6. Arruda-Olson A.M., Reeder G.S., Bell M.R., Weston S.A., Roger V.L. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ Cardiovasc Qual Outcome 2009, 2:656-662.
7. Rudiger A., Burckhardt O.A., Harpes P., Müller S.A., Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med 2006, 24:451-454.
8. Ommen S.R., Hodge D.O., Rodeheffer R.J., McGregor C.G., Thomson S.P., Gibbons R.J. Predictive power of the relative lymphocyte count in patients with advanced heart failure. Circulation 1998, 97:19-22.
9. Milo-Cotter O., Felker G.M., Uriel N., Kaluski E., Edwards C., Rund M.M., Weatherley B.D., Cotter G. Patterns of leukocyte counts on admissions for acute heart failure presentation and outcome results from a community based registry. Int J Cardiol 2011, 148:17-22.
10. Acanfora D., Gheorghiade M., Trojano L., Furgi G., Pasini E., Picone C., Papa A., Iannuzzi G.L., Bonow R.O., Rengo F. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am Heart J 2001, 142:167-173.
11. Uthamalingam S., Patvardhan E.A., Subramanian S., Ahmed W., Martin W., Daley M., Capodilupo R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011, 107:433-438.
12. Kasikcioglu H.A., Cam N. Intravenous positive inotropic therapy for acute decompensated heart failure. Arch Turk Soc Cardiol 2006, 34:316-322.
13. Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., Hutchins S., Leier C.V., LeJemtel T.H., Loh E., Nicklas J., Ogilby D., Singh B.N., Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102:2222-2227.
14. Nieminen M.S., Akkila J., Hasenfuss G., Kleber F.X., Lehtonen L.A., Mitrovic V., Nyquist O., Remme W.J. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1903-1912.
15. Moiseyev V.S., Põder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., Kobalava Z.D., Lehtonen L.A., Laine T., Nieminen M.S., Lie K.I. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23:1422-1432. RUSSLAN Study Investigators.
16. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., Harjola V.P., Mitrovic V., Abdalla M., Sandell E.P., Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
17. Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., Drexler H., Filippatos G., Felix S.B., Gullestad L., Hilfiker-Kleiner D., Janssens S., Latini R., Neubauer G., Paulus W.J., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119-129.
18. Bekwelem W., Lutsey P.L., Loehr L.R., Agarwal S.K., Astor B.C., Guild C., Ballantyne C.M., Folsom A.R. White blood cell count C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2011, 21:739-748.
19. Summers C., Rankin S.M., Condliffe A.M., Singh N., Peters A.M., Chilvers E.R. Neutrophil kinetics in health and disease. Trends Immunol 2010, 31:318-324.
20. Sato Y., Fujiwara H., Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012, 59:1-7.
21. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206.
22. Avgeropoulou C., Andreadou I., Markantonis-Kyroudis S., Demopoulou M., Missovoulos P., Androulakis A., Kallikazaros I. The Ca-sensitizer levosimendan improves oxidative damage BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison with dobutamine. Eur J Heart Fail 2005, 7:882-887.
23. Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., Venetsanou K., Lekakis J., Kremastinos D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005, 96:423-426.
24. Parissis J.T., Adamopoulos S., Antoniades C., Kostakis G., Rigas A., Kyrzopoulos S., Iliodromitis E., Kremastinos D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004, 93:1309-1312.
25. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998, 98:2141-2147.
26. Adamopoulos S., Parissis J.T., Iliodromitis E.K., Paraskevaidis I., Tsiapras D., Farmakis D., Karatzas D., Gheorghiade M., Filippatos G.S., Kremastinos D.T. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006, 98:102-106.
27. Yokoshiki H., Katsube Y., Sunagawa M., Sperelakis N. Levosimendan, a novel Ca2+-sensitizer activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. J Pharmacol Exp Ther 1997, 283:375-383.
28. Adamopoulos S., Parissis J., Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001, 3:517-526.
29. Pereira-Barretto A.C., Carlo C.H., Cardoso J.N., Ochiai M.E., Lima M.V., Curiati M.C., Scipioni A.R., Ramires J.A. Role of BNP levels on the prognosis of decompensated advanced heart failure. Arq Bras Cardiol 2013, 100:281-287.
30. Pagel P.S., Hettrick D.A., Warltier D.C. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996, 119:609-615.
31. Zemljic G., Bunc M., Yazdanbakhsh A.P., Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007, 13:417-421.
32. Araújo J.P., Lourenço P., Azevedo A., Friões F., Rocha-Gonçalves F., Ferreira A., Bettencourt P. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009, 15:256-266.
33. Takahama H., Yokoyama H., Kada A., Sekiguchi K., Fujino M., Funada A., Amaki M., Hasegawa T., Asakura M., Kanzaki H., Anzai T., Kitakaze M. Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes. J Cardiol 2013, 61:58-64.
34. Plischke M., Neuhold S., Kohl M., Heinze G., Sunder-Plassmann G., Pacher R., Hülsmann M. Renal function in heart failure: a disparity between estimating function and predicting mortality risk. Eur J Heart Fail 2013, 15:763-770.
35. Lok D.J., Klip I.T., Lok S.I., Bruggink-André de la Porte P.W., Badings E., van Wijngaarden J., Voors A.A., de Boer R.A., van Veldhuisen D.J., van der Meer P. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013, 112:831.
36. Sato Y., Fujiwara H., Takatsu Y. Cardiac troponin and heart failure in the era of high-sensitivity assays. J Cardiol 2012, 60:160-167.